FrancophonIA/ELRC3.0 huggingface dataset:
English: • The PRAC also considered the currently available data on dose-efficacy and dose-toxicity relationship, and concluded that it was too limited to allow for a formal recommendation for dose reduction as a risk minimisation measure in patients who have not experienced toxicity.
Estonian: • riskihindamiskomitee kaalus ka annuse ja efektiivsuse seose ning annuse ja toksilisuse seose olemasolevaid andmeid ning järeldas, et need on liiga piiratud, et anda ametlikku soovitust annuse vähendamise kui riskivähendusmeetme kohta nendel patsientidel, kellel toksilisust ei ilmne; komitee nõustus siiski, et neid andmeid on tähtis ravimiteabes kajastada;
English: Based on the totality of the data assessed during the procedure and on the advice from the Scientific Advisory Group for oncology, the PRAC concluded that the benefit-risk balance of Iclusig remains favourable taking into account the product information amendments and subject to the risk minimisation measures and additional pharmacovigilance activities agreed.
Estonian: Kõigi menetluses hinnatud andmete põhjal ja onkoloogia teadusnõuanderühma nõuandel järeldas ravimiohutuse järelevalve riskihindamiskomitee, et Iclusigi kasulikkuse ja riski tasakaal on endiselt soodne, kui arvestatakse ravimiteabe muudatusi ning võetakse kokkulepitud riskivähendusmeetmed ja ravimiohutuse järelevalve meetmed.
English: As part of the assessment of potential causes that may lead to an increased occurrence of vascular occlusive events in ponatinib treated patients, molecular mechanisms based on on-target and offtarget effects were discussed.
Estonian: Ponatiniibiga ravitavate patsientide veresoonte oklusiooniga seotud kõrvalnähtude sagedama esinemise võimalike põhjuste arutelu osana käsitleti sihtrühma ja teiste rühmade kõrvaltoimete põhjal molekulaarmehhanisme.
English: • Inclusion of safety and efficacy data following dose reduction in CP-CML patients who have achieved MCyR to inform physicians of the currently available data on dose reduction.
Estonian: • Lisati annuse vähendamise järgsed ohutus- ja efektiivsusandmed nende kroonilises faasis CML-iga patsientide kohta, kellel on tekkinud oluline tsütogeneetiline ravivastus, et teatada arstidele praegu olemasolevad annuse vähendamise andmed.
English: The PRAC is therefore of the opinion that the benefit-risk balance of Iclusig remains favourable taking into account the product information amendments and subject to the risk minimisation measures and additional pharmacovigilance activities agreed.
Estonian: Seega on ravimiohutuse järelevalve riskihindamiskomitee arvamusel, et Iclusigi kasulikkuse ja riski tasakaal on endiselt soodne, kui arvestatakse ravimiteabe muudatusi ning võetakse kokkulepitud riskivähendusmeetmed ja ravimiohutuse järelevalve meetmed.
English: The PRAC also recommended that a dose-ranging study be conducted in patients with CP-CML in order to determine the optimal starting dose of Iclusig and characterise the safety and efficacy of Iclusig following dose reductions after achieving major cytogenetic response.
Estonian: Ravimiohutuse järelevalve riskihindamiskomitee soovitab ka korraldada kroonilises faasis CML-iga patsientidel annuste varieerimise uuringu, et leida Iclusigi optimaalne algannus ning iseloomustada Iclusigi ohutust ja efektiivsust pärast olulise tsütogeneetilise ravivastuse tekke järgset annuse vähendamist.
English: The PRAC has therefore recommended the variation to the terms of the marketing authorisation for Iclusig.
Estonian: Seega soovitab ravimiohutuse järelevalve riskihindamiskomitee muuta Iclusigi müügiloa tingimusi.
English: There is also an association between vascular occlusive events and a risk of cardiac failure as a secondary event.
Estonian: Samutiu on olemas veresoonte oklusiooniga seotud kõrvalnähtude ja südamepuudulikkuse kui sekundaarse kõrvalnähu riski seos.
English: The Product Information for Iclusig was revised to include the following:
Estonian: Iclusigi ravimiteavet muudeti, lisades järgmise teabe.
English: A dose-ranging study will be conducted in patients with CP-CML in order to determine the optimal starting dose of Iclusig and characterise the safety and efficacy of Iclusig following dose reductions after achieving MCyR.
Estonian: Kroonilises faasis CML-iga patsientide kohta korraldatakse annuste varieerimise uuring, et leida Iclusigi optimaalne algannus ning iseloomustada Iclusigi ohutust ja efektiivsust pärast olulise tsütogeneetilise ravivastuse tekke järgset annuse vähendamist.
English: Efficacy data in relation to dose reduction indicates that patients who have been dose reduced maintained response (MCyR and MMR) for the duration of the currently available follow-up.
Estonian: Annuse vähendamisega seotud efektiivsusandmed näitavad, et vähendatud annusega patsientide ravivastus (oluline tsütogeneetiline ravivastus ja oluline molekulaarne ravivastus) püsis praeguste järelkontrolliandmete alusel.
English: Further non-clinical studies will be conducted with the aim to further characterise the potential mechanisms for vascular occlusive events with ponatinib treatment.
Estonian: Ponatiniibi ravis veresoonte oklusiooniga seotud kõrvalnähtude võimalike mehhanismide iseloomustamiseks korraldatakse mittekliinilised lisauuringud.
English: A number of plausible molecular mechanism exists that may contribute to vascular occlusive events.
Estonian: Veresoonte oklusiooniga seotud kõrvalnähte võib põhjustada mitu võimalikku molekulaarmehhanismi.
English: • The PRAC also noted that, although limited, the data in chronic phase CML is indicative of maintenance of response in patients who are dose reduced and therefore it was considered important to generate further data on the dose-efficacy relationship to potentially inform future risk minimisation measures.
Estonian: viitavad need ravivastuse säilimisele vähendatud annusega patsientidel, mispärast on tähtis vaja saada annuse ja efektiivsuse seose kohta lisaandmeid, et selle järgi saaks tulevikus välja töötada riskivähendusmeetmeid.
English: Outcome of a procedure under Article 6(13) of Regulation (EC) 1084/2003 as amended
Estonian: Muudetud määruse (EÜ) nr 1084/2003 artikli 6 lõike 13 alusel toimunud menetluse tulemus
English: The European Commission issued a decision on 26 August 2010.
Estonian: Euroopa Komisjon tegi otsuse 26. augustil 2010.
English: 30 October 2009, 25 January 2010, 22 February 2010, 26 March 2010
Estonian: 30. oktoober 2009, 25. jaanuar 2010, 22. veebruar 2010, 26. märts 2010
English: The variation to the marketing authorisation was rejected because the Member States concluded that the benefit-risk balance of the medicine was unfavourable.
Estonian: Müügiloa muutmise taotlus lükati tagasi, sest liikmesriigid järeldasid, et ravimi kasulikkuse ja riski suhe ei ole soodne.
English: In addition, evidence in support of the proposed dose was insufficient.
Estonian: Samuti ei olnud kavatsetud annust toetavad tõendid piisavad.
English: However, Astra Zeneca was not in agreement with the grounds for refusal and, on 22 May 2009, it referred the matter to the CHMP for arbitration.
Estonian: Astra Zeneca keeldumise põhjustega siiski ei nõustunud ning tegi 22. mail 2009 Euroopa Ravimiametile esildise vahekohtumenetluse alustamiseks.
English: What is Seroquel XR?
Estonian: Mis on Seroquel XR?
English: Prolonged-release means that the active substance is released slowly from the tablet over a few hours.
Estonian: „Pikaajaliselt vabastav“ tähendab, et toimeaine vabaneb tabletist aeglaselt, mitme tunni jooksul.
English: Seroquel XR is authorised in Austria, Belgium, Cyprus, Germany, Denmark, Greece, Spain, Finland, Ireland, Iceland, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, and Sweden under a mutual recognition procedure on the basis of the initial authorisation granted by the ‘reference Member State', the Netherlands, in August 2007.
Estonian: Ravimi Seroquel XR müügiluba anti Austrias, Belgias, Hispaanias, Iirimaal, Islandil, Kreekas, Küprosel, Luksemburgis, Maltal, Madalmaades, Norras, Poolas, Portugalis, Rootsis, Saksamaal, Soomes ja Taanis
English: Seroquel XR is also marketed under other trade names: Seroquel Depot, Seroquel Prolong, and Seroquel SR.
Estonian: Ravimit Seroquel XR turustatakse ka mitme muu nimetuse all: Seroquel Depot, Seroquel Prolong ja Seroquel SR.
English: It is used in patients with schizophrenia, a mental illness with a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).
Estonian: Seda kasutatakse skisofreeniaga patsientidel - skisofreenia on vaimuhaigus, millel on mitmeid sümptomeid, sealhulgas mõtlemis- ja kõnehäired, hallutsinatsioonid (ebareaalsete asjade nägemine või kuulmine), kahtlustamine ja luulud.
English: Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that a new indication for Seroquel XR can be granted.
Estonian: Tuginedes olemasolevatele andmetele ja komiteesisesele teaduslikule arutelule, leidis inimravimite komitee, et ravimile Seroquel XR võib kinnitada uue näidustuse.
English: On 15 May 2009, the Netherlands and all the other concerned Member States rejected a change (variation) to the marketing authorisation to add as a new indication the treatment of recurrent depressive episodes in patients with major depressive disorder (MDD).
Estonian: 15. mail 2009 lükkasid Madalmaad ja kõik teised asjaomased liikmesriigid tagasi müügiloa muutmise taotluse, kus sooviti lisada uus näidustus: korduvate depressiooniepisoodide ravi raske depressiooniga patsientidel.
English: Since these neurotransmitters are involved in schizophrenia and bipolar disorder, quetiapine helps to normalise the activity of the brain, reducing the symptoms of these diseases.
Estonian: Et need neurotransmitterid on seotud skisofreenia ja bipolaarse meeleoluhäirega, aitab kvetiapiin ajutalitlust normaliseerida ja nende haiguste sümptomeid leevendada.
English: Why was Seroquel XR reviewed?
Estonian: Miks ravimi Seroquel XR taotlus uuesti üle vaadati?
English: The European Medicines Agency has completed an arbitration procedure for Seroquel XR and associated names.
Estonian: Euroopa Ravimiamet on lõpetanud ravimi Seroquel XR ja sarnaste nimetuste vahekohtumenetluse.
English: Questions and answers on Seroquel XR and associated names (50, 150, 200, 300 and 400 mg prolonged-release tablets containing quetiapine) EMA/256694/2010
Estonian: Teave ravimi Seroquel XR ja sarnaste nimetuste kohta (50 mg, 150 mg, 200 mg, 300 mg ja 400 mg toimeainet pikaajaliselt vabastavad kvetiapiini sisaldavad tabletid) EMA/256694/2010
English: Not enough data had been submitted to support the restriction to patients not responsive to standard antidepressants.
Estonian: Ei olnud esitatud piisavalt andmeid, mis toetanuks ravimi kasutamise piiramist vaid patsientidega, kes ei reageeri ravile tavapäraste antidepressantidega.
English: The exact mechanism of action of quetiapine is unknown, but it attaches to several receptors on the surface of nerve cells in the brain, including the receptors for the neurotransmitters dopamine and serotonin.
Estonian: Kvetiapiini täpne toimemehhanism ei ole teada, kuid aine seondub aju närvirakkude pinnal mitme retseptoriga, sh neurotransmitterite dopamiini ja serotoniini retseptoritega, mis häirib neurotransmitterite vahendatavaid närvisignaale.
English: Seroquel XR is an antipsychotic medicine that contains the active substance quetiapine.
Estonian: Seroquel XR on antipsühhootikum, mis sisaldab toimeainena kvetiapiini.
English: The indication excluded the use of Seroquel XR as initial treatment, and restricted its use only to patients who cannot be appropriately managed on alternative antidepressant treatment.
Estonian: Näidustus välistas ravimi Seroquel XR kasutamise esmase ravimina ja piiras selle kasutamise vaid patsientidega, keda ei saa sobivalt ravida alternatiivsete antidepressantidega.
English: It is also used for the prevention and treatment of bipolar disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood, as well as episodes of depression.
Estonian: Ravimit kasutatakse ka bipolaarse meeleoluhäire ennetuses ja ravis - see on vaimuhaigus, mille korral patsientide maaniaepisoodid (meeleolu äärmuslik tõus) vahelduvad normaalse meeleolu perioodide ja depressiooniepisoodidega.
English: Questions and answers on Seroquel XR and associated names (50, 150, 200, 300 and 400 mg prolonged-release tablets containing quetiapine)
Estonian: Teave ravimi Seroquel XR ja sarnaste nimetuste kohta (50 mg, 150 mg, 200 mg, 300 mg ja 400 mg toimeainet pikaajaliselt vabastavad kvetiapiini sisaldavad tabletid)
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that Seroquel XR can be used as add-on to ongoing treatment for major depressive episodes in patients with major depressive disorder who have had sub-optimal response to treatment with other antidepressants.
Estonian: Euroopa Ravimiameti inimravimite komitee järeldas, et ravimit Seroquel XR tohib kasutada raskete depressiooniepisoodide täiendava ravimina raskete depressiivhäiretega patsientidel, kui muude antidepressantide ravitulemus ei ole olnud piisav.
English: Seroquel XR is available as prolonged-release tablets.
Estonian: Ravimit Seroquel XR turustatakse toimeainet pikaajaliselt (prolongeeritult) vabastavate tablettidena.
English: The Committee recommended that the medicine be used as add-on to ongoing treatment for major depressive episodes in MDD patients who have had sub-optimal response to monotherapy with another antidepressant.
Estonian: Komitee soovitas ravimit kasutada täiendava ravimina raskete depressiooniepisoodide ravis raskete depressiivhäiretega patsientidel, kes ei reageeri piisavalt muu antidepressandi monoteraapiale.
English: • is pregnant or might be pregnant.
Estonian: • on või võib olla rase.
English: The combination should be avoided.
Estonian: Seda kombinatsiooni tuleb vältida.
English: Terminal half life (t½) is 3.5-4 hours.
Estonian: Terminaalne poolväärtusaeg (t½) on 3,5…4 tundi.
English: Bioavailability is in the order of 15%.
Estonian: Biosaadavus on 15% tasemel.
English: Data are available for up to 2 years' treatment.
Estonian: Andmed on saadaval kuni 2-aastase ravi kohta.
English: The treatment effects on sleep variables were associated with improved parents' well-being.
Estonian: Ravi mõju unemuutujatele seostati lapsevanemate parema heaoluga.
English: DO NOT take Slenyto if you or your child: - is allergic to melatonin or any of the other ingredients of this medicine (listed in section 6).
Estonian: ÄRGE VÕTKE Slenytot, kui teie või teie laps: - on melatoniini või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline;
English: The medicine can help you or your child fall asleep and may help you or your child sleep for longer during the night.
Estonian: Ravim võib aidata teil või teie lapsel magama jääda ning võib aidata teil või teie lapsel öösel kauem magada.
English: Common: may affect between 1 in 100 to 1 in 10 people
Estonian: Sage: võib esineda 1 inimesel 100st kuni 1 inimesel 10st:
English: Other medicines and Slenyto
Estonian: Muud ravimid ja Slenyto
English: Frequency not known (reported from use in adults)
Estonian: Sagedus ei ole teada (teatud kasutamisel täiskasvanute poolt)
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 September 2018
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 20. september 2018
English: Unexpected changes in behaviour, such as aggression, may occur commonly (affecting between 1 in 100 to 1 in 10 people).
Estonian: Ootamatud muutused käitumises, nt agressioon, võivad esineda sageli (1/100 kuni 1/10 inimestest).
English: There is a significant first pass effect with an estimated first pass metabolism of 85%.
Estonian: Esineb oluline esmase passaaži toime koos hinnangulise esmase passaaži metabolismiga 85%.
English: For children and adolescents aged 2-18
Estonian: Lastele ja noorukitele vanuses 2-18 aastat
English: Do not give this medicine to children below the age of 2 years as it has not been tested and its effects are unknown.
Estonian: Alla 2-aastased lapsed Ärge andke seda ravimit alla 2-aastastele lastele, seda ei ole uuritud ja selle toime on teadmata.
English: How much
Estonian: Kui palju
English: Open label treatment period results (91weeks)
Estonian: Avatud raviperioodi tulemused (91 nädalat)
English: Package Leaflet: Information for the user
Estonian: Pakendi infoleht teave kasutajale
English: Autoimmune diseases
Estonian: Autoimmuunhaigused
English: Somnolence, Headache, Sudden onset of sleep
Estonian: Unisus, peavalu, äkiline uinumine
English: Treatment was administered for up to two years.
Estonian: Ravimit manustati kuni kaks aastat.
English: Concomitant use of the following medicinal products should be considered with caution:
Estonian: Järgmiste ravimpreparaatide samaaegsel kasutamisel tuleb olla ettevaatlik:
English: How long
Estonian: Kui kaua
English: 5- or 8-methoxypsoralen
Estonian: 5- või 8-metoksüpsoraleen
English: The tablets should be taken after the evening meal, i.e. on a full stomach.
Estonian: Tablette tuleb võtta pärast õhtusööki (täis kõhuga).
English: What Slenyto is and what it is used for
Estonian: Mis on Slenyto ja milleks seda kasutatakse
English: Do not drink alcohol before, during or after taking Slenyto, because alcohol weakens the effect of the medicine.
Estonian: Ärge jooge alkoholi enne ega pärast Slenyto võtmist ega selle võtmise ajal, sest alkohol vähendab ravimi efektiivsust.
English: A five-fold variability in Cmax between different members of the same sex has also been observed.
Estonian: Täheldatud on ka Cmax viiekordset erinevust samast soost isikute hulgas.
English: It is important to continue taking this medicine to treat the condition.
Estonian: Seisundi ravimiseks on oluline ravimi võtmise jätkamine.
English: As a precautionary measure, it is preferable to avoid the use of melatonin during pregnancy.
Estonian: Ettevaatusabinõuna on soovitatav melatoniini kasutamist raseduse ajal vältida.
English: Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Estonian: Patsiendid, kellel on harvaesinev pärilik galaktoositalumatus, täielik laktaasipuudulikkus või glükoosi-galaktoosi malabsorptsioon, ei tohi seda ravimit võtta.
English: DATE OF REVISION OF THE TEXT {DD month YYYY}
Estonian: TEKSTI LÄBIVAATAMISE KUUPÄEV {PP.KK.AAAA}
English: The absorption of orally ingested melatonin is complete in adults and may be decreased by up to 50% in the elderly.
Estonian: Suukaudselt manustatud melatoniini imendumine täiskasvanutel on täielik ja võib eakatel väheneda kuni 50%.
English: If possible, administration of NSAIDs should be avoided in the evening.
Estonian: Võimalusel tuleb vältida MSPVAde manustamist õhtul.
English: After at least 3 months of treatment, the physician should evaluate the treatment effect and consider stopping treatment if no clinically relevant treatment effect is seen.
Estonian: Pärast vähemalt 3-kuulist raviperioodi peaks arst hindama ravivastust ja kaaluma ravi lõpetamist, kui kliiniliselt olulist ravivastust ei esine.
English: The doctor may want you/your child to stop taking this medicine.
Estonian: Arst võib soovitada teil/teie lapsel selle ravimi võtmine lõpetada.
English: France e-mail: regulatory@neurim.com
Estonian: Prantsusmaa e-post: regulatory@neurim.com
English: Adverse reactions are listed according to MedDRA system organ class and frequency category.
Estonian: Kõrvaltoimed on esitatud MedDRA-organsüsteemi klasside ja esinemissageduse järgi.
English: For social functioning (CGAS), the differences between Slenyto and placebo were small and not statistically significant (Table 1).
Estonian: Sotsiaalses suhtluses (Children's Global Assessment Scale, CGAS) olid Slenyto ja platseebo erinevused väikesed ja statistiliselt ebaolulised (tabel 1).
English: Concomitant use of the following medicinal products is not recommended (see section 4.4):
Estonian: Järgmiste ravimpreparaatide samaaegne kasutamine ei ole soovitatav (vt lõik 4.4):
English: No special treatment is required.
Estonian: Erimeetmeid ei ole vaja rakendada.
English: This leaflet was last revised in { month/YYYY}.
Estonian: Infoleht on viimati uuendatud {kuu/AAAA}.
English: Mood swings, Aggression, Irritability
Estonian: Meeleolumuutused, agressioon, ärrituvus
English: It is for the treatment of insomnia (sleeplessness) when a healthy sleeping routine (such as a regular bedtime and soothing sleeping environment) has not worked well enough.
Estonian: See on näidustatud insomnia (unetuse) raviks, kui tervislik unerutiin (nt regulaarne uneaeg ja rahustav unekeskkond) ei ole olnud piisavalt tõhusad.
English: Slenyto shortens the time it takes to fall asleep and lengthens the duration of sleep.
Estonian: Slenyto lühendab magamajäämise aega ja pikendab une kestust.
English: The effect of any stage of renal impairment on melatonin pharmacokinetics has not been studied.
Estonian: Ühegi neerukahjustuse staadiumi mõju melatoniini farmakokineetikale ei ole uuritud.
English: If an inadequate response has been observed, the dose should be increased to 5 mg, with a maximal dose of 10 mg.
Estonian: Ebapiisava ravivastuse korral tuleks suurendada annust 5 mg-le; maksimaalseks annuseks on 10 mg.
English: Treatment difference (SE)
Estonian: Ravierinevus (SE)
English: Combination with thioridazine and imipramine should be avoided.
Estonian: Kombinatsiooni tioridasiini ja imipramiiniga tuleb vältida.
English: Slenyto should be taken once daily, 0.5-1 hour before bedtime and with or after food.
Estonian: Slenytot tuleb võtta üks kord ööpäevas 0,5…1 tundi enne magamaminekut ja koos söögiga või pärast sööki.
English: Therefore, interactions between melatonin and other active substances as a consequence of their effect on CYP1A enzymes is possible.
Estonian: Seega on melatoniini ja teiste toimeainete vahelised koostoimed võimalikud nende mõju tõttu CYP1A ensüümidele.
English: Slenyto should be taken in the evening, 30 to 60 minutes before bedtime.
Estonian: Slenytot tuleb võtta õhtul, 30…60 minutit enne magamaminekut.
English: If overdose occurs, drowsiness is to be expected.
Estonian: Üleannustamise korral on ootuspärane uimasuse teke.
English: The tablets should be swallowed whole and NOT broken, crushed or chewed.
Estonian: Tablett tuleb neelata tervelt, seda EI TOHI purustada, peenestada ega närida.
English: In the absence of specific studies in children, the drug interactions with melatonin are those known in adults.
Estonian: Kuna puuduvad spetsiifilised uuringud lastega, siis on koostoimed melatoniiniga teada ainult täiskasvanutel.
English: The patient should be monitored at regular intervals (at least every 6 months) to check that Slenyto is still the most appropriate treatment.
Estonian: Patsienti tuleb regulaarselt (vähemalt iga 6 kuu tagant) jälgida, et kontrollida, kas Slenyto on endiselt lapse jaoks õige ravim.
English: Please tell your doctor if you or your child starts or stops smoking during treatment.
Estonian: Palun informeerige oma arsti, kui teie või teie laps ravi ajal suitsetamisest loobute või suitsetamisega alustate.
English: (used to induce sleep)
Estonian: (kasutatakse une tekitamiseks)
English: After 2 weeks withdrawal on placebo, a descriptive reduction in most scores was seen but levels were still significantly better than baseline levels with no signs of rebound effects.
Estonian: Pärast 2-nädalast lõpp-perioodi platseeboga täheldati enamike skooride deskriptiivset langust, kuid tasemed olid ikkagi oluliselt paremad kui algtasemed ning tagasilöögiefekti ei täheldatud.
English: Children under 2 years old
Estonian: Lapsed (vanus alla 2 aasta)
English: Pharmacotherapeutic group: Psycholeptics, melatonin receptor agonists, ATC code: N05CH01 Mechanism of action
Estonian: Farmakoterapeutiline rühm: psühholeptikumid, melatoniiniretseptori agonistid, ATC-kood: N05CH01